文献速递前列腺增生与排尿功能障碍

MOSES™技术在钬激光前列腺剜除术中的前瞻性双盲随机对照试验

MOSESTM Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Controlled Trial.
PubMed 文献 · J Urol · 2021-02-22

该单中心前瞻性双盲随机对照试验将60例BPH患者1:1分配至MOSES技术钬激光前列腺剜除术组或传统钬激光前列腺剜除术组,主要评价手术时间差异。结果显示MOSES组总手术时间、剜除时间、止血时间更短且失血量更少,而功能结局与并发症无差异。

要点

  • MOSES组总手术时间显著短于传统组(平均101 vs 126分钟,p<0.01)。
  • MOSES组剜除时间(68 vs 80分钟,p=0.03)和止血时间(18 vs 29分钟,p<0.01)更短。
  • MOSES组失血量更少(血细胞比容变化平均-6.3% vs -9.0%,p=0.03),功能与安全结局无差异。

核心结论

  • MOSES技术可改善钬激光前列腺剜除术的手术时间并减少失血量,功能结局与并发症和传统技术相当。

研究设计与样本

  • 单中心、前瞻性、双盲、随机对照试验,按1:1随机分组,共分析60例患者(MOSES组30例,传统组30例),主要终点为手术时间差异。

主要发现

  • MOSES组总手术时间平均101分钟,传统组126分钟,p<0.01,多因素线性回归后差异仍显著。
  • MOSES组剜除时间平均68分钟,传统组80分钟,p=0.03。
  • MOSES组止血时间平均18分钟,传统组29分钟,p<0.01。
  • MOSES组术后血细胞比容变化平均-6.3%,传统组-9.0%,p=0.03,提示失血量更少。
  • 随访6周时功能结局与并发症无差异。

关键数值与推荐

  • 总手术时间:MOSES组平均101分钟 vs 传统组126分钟,p<0.01。
  • 剜除时间:MOSES组平均68分钟 vs 传统组80分钟,p=0.03。
  • 止血时间:MOSES组平均18分钟 vs 传统组29分钟,p<0.01。
  • 血细胞比容变化:MOSES组平均-6.3% vs 传统组-9.0%,p=0.03。

临床怎么用

  • 在BPH行钬激光前列腺剜除术时,可考虑使用MOSES技术以缩短手术时间和减少失血量。
  • MOSES技术不增加并发症风险,功能结局与传统技术相当。

局限性

  • 单中心研究,样本量60例,随访6周,长期结局未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Holmium laser enucleation of the prostate has proven to be efficacious and safe for the treatment of benign prostatic hyperplasia. New laser technologies, such as the MOSES™ pulse laser system, improve energy delivery and may improve operative times. We sought to prospectively evaluate holmium laser enucleation of the prostate using MOSES technology in a double-blind randomized controlled trial. MATERIALS AND METHODS: This is a single-center, prospective, double-blind, randomized controlled trial comparing holmium laser enucleation of the prostate using MOSES technology to holmium laser enucleation of the prostate. Patients were randomized in a 1:1 fashion. The study was powered to evaluate for a difference in operative time. Secondary end points included enucleation, morcellation, and hemostasis times, as well as blood loss, functional outcomes and complications 6 weeks postoperatively. RESULTS: A total of 60 patients were analyzed without difference in preoperative characteristics in either group (holmium laser enucleation of the prostate using MOSES technology: 30/60, 50%, holmium laser enucleation of the prostate: 30/60, 50%). Shorter total operative time was seen in the holmium laser enucleation of the prostate using MOSES technology group compared to the holmium laser enucleation of the prostate group (mean: 101 vs. 126 minutes, p <0.01). This difference remained significant on multiple linear regression. Additionally, the holmium laser enucleation of the prostate using MOSES technology group had shorter enucleation times (mean: 68 vs. 80 minutes, p=0.03), hemostasis time (mean: 18 vs. 29 minutes, p <0.01), and less blood loss (mean: -6.3 vs. -9.0%, p=0.03), measured by a smaller change in hematocrit postoperatively, compared to the traditional holmium laser enucleation of the prostate. There was no difference in functional or safety outcomes at followup. CONCLUSIONS: We report the results of a prospective, double-blind, randomized controlled trial comparing holmium laser enucleation of the prostate using MOSES technology to traditional holmium laser enucleation of the prostate. MOSES technology resulted in an improvement in operative time and a reduction in blood loss with comparable functional outcomes and complications compared to traditional holmium laser enucleation of the prostate.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kavoussi NL, Nimmagadda N, Robles J, et al. MOSESTM Technology for Holmium Laser Enucleation of the Prostate: A Prospective Double-Blind Randomized Controlled Trial. J Urol. 2021. PMID: 33617333. doi:10.1097/JU.0000000000001693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。